<DOC>
	<DOCNO>NCT02671422</DOCNO>
	<brief_summary>At present approve predictive tumour- serum-derived biomarkers guide usage anti-angiogenic therapy patient adenocarcinoma NSCLC.The objective NIS examine whether genetic/genomic marker ( alone combine clinical covariates ) could use predict OS NSCLC patient eligible treatment Vargatef® . The investigation study exploratory nature consider hypothesis generate . The result investigation may help expand understand disease response Vargatef® .</brief_summary>
	<brief_title>LUME BioNIS : Biomarker Study Patients With NSCLC</brief_title>
	<detailed_description>Purpose :</detailed_description>
	<mesh_term>Carcinoma , Non-Small-Cell Lung</mesh_term>
	<criteria>Inclusion criterion : Age = 18 year . Women men locally advance , metastatic locally recurrent NSCLC histology adenocarcinoma . Signed date write informed consent . Vargatef ® initiate administered accordance SPC . Available fixed paraffin embed ( FPE ) tumour tissue routinely obtain diagnosis and/or rebiopsy initiation first line treatment ( either block slide , minimum 10 slide 20 slide possible 5µm thickness ) . Exclusion criterion : Any contraindication Vargatef® docetaxel specify respective label . Vargatef® initiate 7 day prior inclusion NIS . Patients participate simultaneously clinical trial .</criteria>
	<gender>All</gender>
	<minimum_age>18 Years</minimum_age>
	<maximum_age>N/A</maximum_age>
	<verification_date>March 2017</verification_date>
</DOC>